miRagen Announces New Clinical Data for Cobomarsen in ATLL Patients at the 19th Annual HTLV Congress in Lima, Peru
April 26, 2019 07:00 ET
|
Miragen Therapeutics, Inc.
Continued evidence of disease stabilization observed in ATLL patients treated with cobomarsen for up to 16 monthsCobomarsen allowed for rapid bone marrow recovery following chemotherapyIn most...
miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8th
April 25, 2019 08:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., April 25, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook
March 13, 2019 16:05 ET
|
Miragen Therapeutics, Inc.
Cobomarsen tested in clinical trials for three different types of blood cancersMultiple clinical sites open and actively recruiting in the global Phase 2 SOLAR clinical trial of cobomarsen in CTCLData...
miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference
March 06, 2019 08:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results and Host a Conference Call on March 13th
February 20, 2019 08:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Feb. 20, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen
January 10, 2019 07:00 ET
|
Miragen Therapeutics, Inc.
50% of cutaneous T-cell lymphoma patients treated with 300mg IV infusion achieved objective response lasting for greater than four months (ORR4)Evidence of disease stabilization in five adult T-cell...
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum
December 20, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman
December 05, 2018 16:05 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Dec. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
December 02, 2018 17:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Dec. 02, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 07, 2018 16:01 ET
|
Miragen Therapeutics, Inc.
Continued advancements of three clinical stage microRNA-targeted product candidates currently being evaluated for multiple potential indications in four clinical trialsGlobal Phase 2 SOLAR clinical...